ArticleBMJ open2023

First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis.

Zhiwei Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.